本文選題：咳嗽變異性哮喘　切入點(diǎn)：兒童　出處：《中國(guó)實(shí)驗(yàn)方劑學(xué)雜志》2017年18期 　論文類(lèi)型：期刊論文

【摘要】：目的:評(píng)價(jià)小兒治哮靈片對(duì)發(fā)作期咳嗽變異性哮喘(CVA)的臨床療效及對(duì)氣道反應(yīng)性和慢性炎癥反應(yīng)的影響。方法:將170例發(fā)作期CVA患兒,采用區(qū)組隨機(jī)按數(shù)字表法分為對(duì)照組和觀察組各85例。兩組患兒均采用布地奈德氣霧劑+孟魯司特鈉咀嚼片進(jìn)行治療,觀察組加服小兒治哮靈片。兩組療程均為4周,并進(jìn)行16周的隨訪。進(jìn)行日間咳嗽、夜間咳嗽情況和咳嗽視覺(jué)模擬(VAS)評(píng)分;進(jìn)行治療前后萊塞斯特咳嗽問(wèn)卷(LCQ)評(píng)分和中醫(yī)證候評(píng)分;記錄咳嗽緩解時(shí)間和16周內(nèi)的復(fù)發(fā)情況;進(jìn)行治療前后氣道反應(yīng)檢測(cè);進(jìn)行治療前后白細(xì)胞介素-4(IL-4),IL-5,IL-13,嗜酸性粒細(xì)胞(EOS)和血清免疫球蛋白(Ig E)檢測(cè)。結(jié)果:觀察組中醫(yī)療效總有效率為93.59%,高于對(duì)照組的81.33%(χ~2=5.281,P0.05);治療后觀察組患兒日間咳嗽、夜間咳嗽、咳嗽總積分及咳嗽VAS評(píng)分均低于對(duì)照組(P0.01);觀察組平均咳嗽緩解時(shí)間短于對(duì)照組(P0.01);在16周的隨訪期中,觀察組復(fù)發(fā)率為39.74%,低于對(duì)照組的61.33%(χ~2=5.281,P0.05),觀察組平均復(fù)發(fā)次數(shù)低于對(duì)照組(P0.01);治療后觀察組LCQ量表2個(gè)維度評(píng)分和總分均高于對(duì)照組(P0.01);觀察組患兒血清IL-4,IL-5,IL-13,總Ig E和EOS水平均低于對(duì)照組(P0.01);觀察組患兒最小誘發(fā)累積劑量(Dmin)和PD35水平均高于對(duì)照組(P0.01)。結(jié)論:小兒治哮靈片治療發(fā)作期咳嗽變異性哮喘,能進(jìn)一步的緩解咳嗽等臨床癥狀,提高患者的生活質(zhì)量,并能降低復(fù)發(fā)頻率,其作用機(jī)制可能是通過(guò)減輕氣道炎癥反應(yīng)、降低氣道高反應(yīng)性來(lái)實(shí)現(xiàn)的。
[Abstract]:Objective: to evaluate the clinical effect of Xiaojixiaoling tablet on cough variant asthma (CVA) and its effect on airway reactivity and chronic inflammation. Group A was randomly divided into control group (n = 85) and observation group (n = 85) according to the method of digital table. The two groups were treated with budesonide aerosol montelukast sodium chewable tablet. The patients were followed up for 16 weeks. The scores of day cough, night cough and visual simulated cough (VAS), Lysst cough questionnaire (LCQQ) and TCM syndromes were evaluated before and after treatment, the time of cough remission and the recurrence of cough within 16 weeks were recorded. Airway reaction was measured before and after treatment. IL-5 IL-13, eosinophilic granulocyte (EOS) and serum immunoglobulin (Ig E) were detected before and after treatment. Results: the total effective rate of TCM in the observation group was 93.59, higher than that in the control group (81.33). The total score of cough and VAS score of cough were lower than those of the control group (P 0.01), the average cough relief time of the observation group was shorter than that of the control group (P 0.01). The recurrence rate of the observation group was 39.74, which was lower than that of the control group (61.33%). The average number of recurrence in the observation group was lower than that in the control group (P 0.01). After treatment, the two dimensional scores and total scores of the LCQ scale in the observation group were higher than those in the control group (P 0.01), and the levels of IL-4 IL-5 IL-13, total IgE and EOS in the observation group were higher than those in the control group. Both of them were lower than those of the control group (P 0.01), and the levels of minimum cumulative dose (min) and PD35 in the observation group were higher than those in the control group (P 0.01). It can further alleviate the clinical symptoms such as cough, improve the quality of life of patients, and reduce the recurrence rate. The mechanism may be achieved by reducing airway inflammation and airway hyperresponsiveness.
【作者單位】： 濰坊市益都中心醫(yī)院;南昌大學(xué)醫(yī)學(xué)院;山東省立醫(yī)院;
【基金】：國(guó)家自然科學(xué)基金項(xiàng)目(81301556)
【分類(lèi)號(hào)】：R272

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉云昊;劉乾生;易帆;;中西醫(yī)結(jié)合診治小兒咳嗽變異性哮喘[J];陜西中醫(yī)藥大學(xué)學(xué)報(bào);2017年01期

2 馮曉純;段曉征;孫麗平;林雙竹;王銳;劉健;;中醫(yī)兒科臨床診療指南·小兒咳嗽變異性哮喘(制訂)[J];中醫(yī)兒科雜志;2016年05期

3 王瑞;劉施吟;;兒童咳嗽變異性哮喘中醫(yī)研究進(jìn)展[J];中醫(yī)臨床研究;2016年26期

4 李倩;李立維;劉君;武國(guó)利;;孟魯司特鈉對(duì)咳嗽變異性哮喘患者IL-4、IL-10及肺功能的影響[J];臨床肺科雜志;2016年08期

5 鮑一笑;陳Z，

本文編號(hào)：1621520